February 5, 2024
QurAlis to Participate in Upcoming Investor Conferences in February
CAMBRIDGE, Mass., February 5, 2024 – QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that will alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will present a corporate overview at the following investor conferences in February.
20th BioCapital Europe (February 7-8, 2024)
Date: Thursday, February 8, 2024
Time:
Location: 2:40 PM CET/8:40 AM ET
Amsterdam, The Netherlands
Evercore ISI 2024 Emerging Biotech Conference (February 28-29, 2024)
Date: Thursday, February 29, 2024
Time:
Location: 10:10 AM ET
Virtual
The QurAlis corporate presentation can be accessed by visiting the presentations section of the Company’s website at www.quralis.com.
About QurAlis Corporation
At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers. For more information, please visit www.quralis.com or follow us on Twitter @QurAlisCo.
